Evidence map›Paper›PMID 29799059›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2019

Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities.

Toshiyuki Tanahashi, Kazuhiro Yoshida, Kazuya Yamaguchi, Naoki Okumura, Atsushi Takeno, Kazumasa Fujitani, Norimasa Fukushima, Nobuhiro Takiguchi, Yasunori Nishida, Narikazu Boku and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Is surgery the best treatment for elderly gastric cancer patients?World journal of gastrointestinal surgery · 2021
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Toshiyuki TanahashiDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Kazuhiro YoshidaDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan. kyoshida@gifu-u.ac.jp.
Kazuya YamaguchiDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
Naoki OkumuraDepartment of Surgery, Gifu Municipal Hospital, Gifu, Japan.
Atsushi TakenoDepartment of Surgery, Kansai Rosai Hospital, Amagasaki, Japan.
Kazumasa FujitaniDepartment of Surgery, Osaka Prefectural General Medical Center, Osaka, Japan.
Norimasa FukushimaDepartment of Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Nobuhiro TakiguchiDepartment of General Surgery, Chiba Cancer Center, Chiba, Japan.
Yasunori NishidaDepartment of Surgery, Keiyuukai Sapporo Hospital, Sapporo, Japan.
Narikazu BokuGastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
Takaki YoshikawaDepartment of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Masanori TerashimaDivision of Gastric Surgery, Shizuoka Cancer Center, Sunto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Japan, S-1 adjuvant chemotherapy for 1 year is the standard of care for the treatment of stage II and III patients under 80 years old with gastric cancer after curative operation. However, the feasibility of S-1 chemotherapy in patients over 80 years old has not yet been elucidated.

methodsTo clarify the current treatment situation and feasibility of S-1 treatment in patients over 80 years old, a questionnaire survey of the patients treated from January 2011 to December 2012 was conducted at 58 member institutions of the Stomach Cancer Study Group of the JCOG (Japan Clinical Oncology Group).

resultsGastrectomy was performed in 15,573 patients of all ages, and 1,660 (10.7%) patients were over 80 years of age. Of these elderly patients, 661 (4.2%) were diagnosed as stage II and III. While S-1 adjuvant chemotherapy was recommended to 248 (37.5%) of the stageII/III patients, only 99 (15.0%) of them actually received S-1. Interestingly, the creatinine clearance rate was between 30 and 80 mL/min in 87 (87.9%) of the patients suggesting that S-1 dose modification should be considered. Moreover, S-1 compliance was poor in patients with more than 15% body weight loss.

conclusionIn general practice, surgery alone can be regarded as the standard of care for stage II and III gastric cancer patients over 80 years old. The feasibility and efficacy of S-1 adjuvant chemotherapy should be elucidated in a randomized control trial considering the vulnerabilities of the elderly.

Indexed as

Aged, 80 and overAntimetabolites, AntineoplasticChemotherapy, AdjuvantDrug CombinationsFemaleGastrectomyHumansMaleOxonic AcidPractice Patterns, Physicians'Stomach NeoplasmsSurveys and QuestionnairesTegafurAntimetabolites, AntineoplasticDrug CombinationsOxonic AcidS 1 (combination)TegafurAdjuvant chemotherapyElderly patientsGastric cancerS-1

Identifiers

PMID29799059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.